Connection

JENNIFER LEIGH MCQUADE to Humans

This is a "connection" page, showing publications JENNIFER LEIGH MCQUADE has written about Humans.
Connection Strength

0.470
  1. Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome. Front Immunol. 2024; 15:1409414.
    View in: PubMed
    Score: 0.019
  2. The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms. Cells. 2023 10 31; 12(21).
    View in: PubMed
    Score: 0.018
  3. Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma. Clin Cancer Res. 2023 01 04; 29(1):154-164.
    View in: PubMed
    Score: 0.017
  4. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol. 2023 01 01; 9(1):102-111.
    View in: PubMed
    Score: 0.017
  5. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers. Curr Oncol Rep. 2020 06 24; 22(7):74.
    View in: PubMed
    Score: 0.014
  6. Nutrition and Cancer in the Microbiome Era. Trends Cancer. 2019 09; 5(9):521-524.
    View in: PubMed
    Score: 0.013
  7. Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. Curr Oncol Rep. 2019 07 01; 21(8):72.
    View in: PubMed
    Score: 0.013
  8. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019 02; 20(2):e77-e91.
    View in: PubMed
    Score: 0.013
  9. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer. 2018 Dec 19; 18(1):1274.
    View in: PubMed
    Score: 0.013
  10. Sex as a predictor of response to cancer immunotherapy. Lancet Oncol. 2018 08; 19(8):e376.
    View in: PubMed
    Score: 0.012
  11. Body-mass index and metastatic melanoma outcomes - Authors' reply. Lancet Oncol. 2018 05; 19(5):e227-e228.
    View in: PubMed
    Score: 0.012
  12. Estrogen returns to the stage in melanoma. Pigment Cell Melanoma Res. 2018 09; 31(5):554-555.
    View in: PubMed
    Score: 0.012
  13. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.012
  14. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016 12; 26(6):604-608.
    View in: PubMed
    Score: 0.011
  15. Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: a randomized controlled trial. Psychooncology. 2017 Nov; 26(11):1936-1943.
    View in: PubMed
    Score: 0.011
  16. Effects of self-management, education and specific exercises, delivered by health professionals, in patients with osteoarthritis of the knee. BMC Musculoskelet Disord. 2008 Oct 02; 9:133.
    View in: PubMed
    Score: 0.006
  17. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024 Dec 01; 31(12).
    View in: PubMed
    Score: 0.005
  18. The role of area deprivation index in health care disruptions among cancer survivors during the SARS-CoV-2 pandemic. Public Health. 2024 Jul; 232:52-60.
    View in: PubMed
    Score: 0.005
  19. Impact of COVID-19-related experiences on health-related quality of life in cancer survivors in the United States. PLoS One. 2024; 19(3):e0297077.
    View in: PubMed
    Score: 0.005
  20. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024 01 31; 12(1).
    View in: PubMed
    Score: 0.005
  21. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw. 2024 01 08; 22(5).
    View in: PubMed
    Score: 0.005
  22. Melanoma and microbiota: Current understanding and future directions. Cancer Cell. 2024 01 08; 42(1):16-34.
    View in: PubMed
    Score: 0.005
  23. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine. 2023 Dec; 98:104873.
    View in: PubMed
    Score: 0.004
  24. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. Eur J Cancer. 2024 Jan; 196:113441.
    View in: PubMed
    Score: 0.004
  25. Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell Melanoma Res. 2023 11; 36(6):542-556.
    View in: PubMed
    Score: 0.004
  26. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma. JAMA Dermatol. 2023 10 01; 159(10):1076-1084.
    View in: PubMed
    Score: 0.004
  27. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
    View in: PubMed
    Score: 0.004
  28. Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Ann Oncol. 2023 09; 34(9):796-805.
    View in: PubMed
    Score: 0.004
  29. Obesity and renal cell carcinoma: Biological mechanisms and perspectives. Semin Cancer Biol. 2023 09; 94:21-33.
    View in: PubMed
    Score: 0.004
  30. Diversity, equity, and inclusion in the melanoma research community. Pigment Cell Melanoma Res. 2023 09; 36(5):441-447.
    View in: PubMed
    Score: 0.004
  31. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology. 2023 04 17; 164(6).
    View in: PubMed
    Score: 0.004
  32. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
    View in: PubMed
    Score: 0.004
  33. Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancer. CA Cancer J Clin. 2023 Jul-Aug; 73(4):425-442.
    View in: PubMed
    Score: 0.004
  34. Bodywide ecological interventions on cancer. Nat Med. 2023 01; 29(1):59-74.
    View in: PubMed
    Score: 0.004
  35. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
    View in: PubMed
    Score: 0.004
  36. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol. 2022 Dec; 167(3):483-489.
    View in: PubMed
    Score: 0.004
  37. Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis. J Clin Oncol. 2023 01 20; 41(3):579-589.
    View in: PubMed
    Score: 0.004
  38. Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. Melanoma Res. 2022 12 01; 32(6):451-459.
    View in: PubMed
    Score: 0.004
  39. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.004
  40. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 05 02; 28(9):1911-1924.
    View in: PubMed
    Score: 0.004
  41. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab. Dermatol Online J. 2022 Mar 15; 28(2).
    View in: PubMed
    Score: 0.004
  42. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022 04 01; 40(10):1068-1080.
    View in: PubMed
    Score: 0.004
  43. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.004
  44. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2022 07; 142(7):2046-2049.e3.
    View in: PubMed
    Score: 0.004
  45. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 2022 03 01; 128(5):975-983.
    View in: PubMed
    Score: 0.004
  46. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.004
  47. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. Am J Clin Oncol. 2021 08 01; 44(8):402-408.
    View in: PubMed
    Score: 0.004
  48. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.004
  49. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl Med. 2021 06 02; 19(1):238.
    View in: PubMed
    Score: 0.004
  50. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.004
  51. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021 07; 32(7):917-925.
    View in: PubMed
    Score: 0.004
  52. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Med. 2021 04; 10(7):2293-2299.
    View in: PubMed
    Score: 0.004
  53. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer. 2021 01; 9(1).
    View in: PubMed
    Score: 0.004
  54. The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies. Mol Cancer Ther. 2021 03; 20(3):500-511.
    View in: PubMed
    Score: 0.004
  55. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
    View in: PubMed
    Score: 0.004
  56. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head Neck. 2020 11; 42(11):E35-E42.
    View in: PubMed
    Score: 0.004
  57. The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. J Immunother Cancer. 2020 08; 8(2).
    View in: PubMed
    Score: 0.004
  58. Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer. 2020 08 15; 126(16):3708-3718.
    View in: PubMed
    Score: 0.004
  59. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970.
    View in: PubMed
    Score: 0.003
  60. Gut Microbiome Modulates Response to Cancer Immunotherapy. Dig Dis Sci. 2020 03; 65(3):885-896.
    View in: PubMed
    Score: 0.003
  61. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Sci Rep. 2020 01 29; 10(1):1456.
    View in: PubMed
    Score: 0.003
  62. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.003
  63. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. Oncologist. 2020 03; 25(3):e602-e605.
    View in: PubMed
    Score: 0.003
  64. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6429-6442.
    View in: PubMed
    Score: 0.003
  65. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov. 2019 05; 9(5):628-645.
    View in: PubMed
    Score: 0.003
  66. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clin Cancer Res. 2019 02 15; 25(4):1272-1279.
    View in: PubMed
    Score: 0.003
  67. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV?or hepatitis B/C infection. Eur J Cancer. 2018 11; 104:137-144.
    View in: PubMed
    Score: 0.003
  68. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res. 2018 11 01; 24(21):5347-5356.
    View in: PubMed
    Score: 0.003
  69. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
    View in: PubMed
    Score: 0.003
  70. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.003
  71. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma Res. 2018 01; 31(1):11-30.
    View in: PubMed
    Score: 0.003
  72. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
    View in: PubMed
    Score: 0.003
  73. Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. Cancer. 2017 06 01; 123(11):1989-1997.
    View in: PubMed
    Score: 0.003
  74. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Support Care Cancer. 2017 07; 25(7):2103-2109.
    View in: PubMed
    Score: 0.003
  75. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017; 5:8.
    View in: PubMed
    Score: 0.003
  76. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017 02 01; 28(2):368-376.
    View in: PubMed
    Score: 0.003
  77. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.003
  78. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.003
  79. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One. 2016; 11(5):e0154985.
    View in: PubMed
    Score: 0.003
  80. Differences in quality of life between American and Chinese breast cancer survivors. Support Care Cancer. 2016 09; 24(9):3775-82.
    View in: PubMed
    Score: 0.003
  81. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.003
  82. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer. 2015 Nov 15; 121(22):3948-58.
    View in: PubMed
    Score: 0.003
  83. Acupuncture for symptom management in cancer care: an update. Curr Oncol Rep. 2014 Dec; 16(12):418.
    View in: PubMed
    Score: 0.002
  84. Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics. 2013 Aug; 194(4):987-96.
    View in: PubMed
    Score: 0.002
  85. Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial. Cancer. 2013 May 01; 119(9):1690-8.
    View in: PubMed
    Score: 0.002
  86. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol. 2013 Mar 01; 31(7):952-60.
    View in: PubMed
    Score: 0.002
  87. Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance. Bone Marrow Transplant. 2012 Aug; 47(8):1082-6.
    View in: PubMed
    Score: 0.002
  88. Electro-acupuncture to prevent prolonged postoperative ileus: a randomized clinical trial. World J Gastroenterol. 2010 Jan 07; 16(1):104-11.
    View in: PubMed
    Score: 0.002
  89. Sense of control and adjustment to breast cancer: the importance of balancing control coping styles. Behav Med. 1999; 25(3):101-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.